Compare Nerdwallet Inc (NRDS) vs Novartis AG (NVS) Price & Performance

NRDS trades at $9.12, down 1.51% today, with a bearish technical signal but strong fundamentals including a 93% gross margin and consistent earnings beats. Revenue grew to $836.6M in 2025, with net income reaching $48.7M. Positive analyst sentiment includes a $12.75 consensus target, though technical indicators show near-term pressure.

The stock offers value with a P/E of 9.87 and upside potential from analyst targets, but faces risks from competitive pressures and reliance on consumer financial health. Earnings growth and margin expansion are key catalysts, yet macroeconomic sensitivity could impact performance.

Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.

The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.